Recent Finacing
Recent Raise
RIGImmune develops stem-loop RNA therapeutics that selectively modulate the RIG‑I pathway, advancing intranasal candidate RIG‑101 for treatment and adjuvant use against respiratory RNA viruses.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at RIGImmune.
